Comments
Loading...
Helix Biomedix Analyst Ratings and Price Targets | OTC:HXBM | Benzinga
Helix Biomedix Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Helix Biomedix Corp from these most-recent analyst ratings.
Analyst Ratings for Helix Biomedix
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Helix Biomedix (HXBM) stock?
There is no price target for Helix Biomedix
What is the most recent analyst rating for Helix Biomedix (HXBM)?
There is no analyst for Helix Biomedix
When was the last upgrade for Helix Biomedix (HXBM)?
There is no last upgrade for Helix Biomedix
When was the last downgrade for Helix Biomedix (HXBM)?
There is no last downgrade for Helix Biomedix.
When is the next analyst rating going to be posted or updated for Helix Biomedix (HXBM)?
There is no next analyst rating for Helix Biomedix.
Is the Analyst Rating Helix Biomedix (HXBM) correct?
There is no next analyst rating for Helix Biomedix.
Browse analyst ratings and price targets on all stocks.